In the run-up to the US presidential election, which is set to happen in November 2024, the right-wing non-profit America First Policy Institute has pointed to patent and drug approval systems as one of the reasons for drug unaffordability in the country.
While AFPI refers to itself as a non-partisan organization, the group was launched by alumni of former president Donald Trump’s administration